Lonza’s Bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software for biomanufacturing. Have your catalog and lot numbers ready and click the link.

We are a fully integrated CDMO that offers innovative development and manufacturing services and technologies from late phase drug discovery to market supply, from drug substance to drug product across a variety of molecule types. Drug candidates in the development pipeline are increasingly innovative and complex.

The Biologics division comprises a full-service CDMO, providing development and manufacturing services to pharma and biotech companies across a wide range of biologic modalities, including mammalian, microbial, bioconjugates, mRNA, and drug product services.

Here at Lonza, we are helping to drive innovation and change in the Biologics industry. Our Offering. Biologics. Mammalian. Microbial. ADCs / Bioconjugates. Drug Product. ... Lonza has a reputation for manufacturing high quality products that live up to the ‘Swiss made’ label, and I was curious to know the recipe behind this success and ...

Our Bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software for biomanufacturing. PYROGENT™-5000 Bulk Kit 2250 Test Kit, contains matched endotoxin and reconstitution buffer. Assay sensitivity: 0.01 to …

Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies.

Discover how Lonza Biologics’ end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with their extensive drug substance network across diverse modalities. ... This expansion is dedicated to biologics filling in various formats, including vials—offered as liquid or lyophilized products—as well ...

Nov 25, 2024 · Lonza recently completed the expansion of its new drug product services facility in Basel Switzerland, adding a new facility for quality control and bioanalytics to support early and late-stage clinical and commercial drug product (DP) quality control (QC).

May 7, 2021 · Lonza to up mammalian bioreactor capacity by 136,000L. Lonza has invested $935 million to expand its mammalian manufacturing facilities in Visp, Switzerland and Portsmouth, US.

Lonza is one of the world’s largest healthcare manufacturing organizations, helping pharmaceutical, biotech and nutrition companies to bring their treatments to market.